The management of human epidermal growth factor receptor (HER2)–positive breast cancer
(BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and …

Human epidermal growth factor receptor 2 (HER2) is overexpressed and/or amplified in
approximately 20% of breast cancers, conferring an aggressive tumor behavior but also an …

Cases of human epidermal growth factor receptor 2 (HER2)–positive breast cancer
represent approximately 15% to 20% of all breast cancers. Historically, this subtype of breast …

Significant advances have occurred in the treatment of human epidermal growth factor
receptor 2 (HER2)‐positive breast cancer that have changed its natural history. The addition …

Targeting human epidermal growth factor receptor 2 (HER2) during or in sequence with
chemotherapy improves overall survival in metastatic and early HER2-overexpressing …

Over the past 2 decades, there has been an extraordinary progress in the regimens
developed for the treatment of human epidermal growth factor receptor 2 (HER2)-positive …

The introduction of anti-HER2 therapies to the treatment of patients with HER2-positive
breast cancer has led to dramatic improvements in survival in both early and advanced …

Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …

The advent of HER2-directed therapies has significantly improved the outlook for patients
with HER2-positive early stage breast cancer. However, a significant proportion of these …

Purpose A Cancer Care Ontario (CCO) guideline on the selection of optimal adjuvant
chemotherapy regimens for early breast cancer including adjuvant targeted therapy for …